These results, taken together, indicate that appropriate RAB6B and RAB27A levels and their subsequent prenylation define the growth suppressive effect of HMGCR-inhibitor treatment in this subset of BRAF-inhibitor resistant melanoma cells. Here, BRAF is linked to melanoma.